器官晶片新创久浪智医完成2亿元A轮，老股东全数跟投
Meet创业小聚 · 2026-10-19
2024年成立的久浪智医以AI结合器官晶片加速药物验证，完成2亿元（约600万美元）A轮，既有投资人全数参与，资金将用于扩充实验设施与海外布局。其吸入式肺部晶片入选美国FNIH试点计划，已服务逾30家客户并设立美国子公司。
Organ-on-chip startup Anivance AI closes NT$200 million Series A with all existing investors following on
Anivance AI, founded in 2024 to speed drug testing with AI and organ-on-chip models, has raised a NT$200 million (about US$6 million) Series A in which every existing investor took part. Funds go to lab infrastructure and overseas expansion; its inhalation lung-chip was picked for a US FNIH pilot, and it has over 30 clients and a US subsidiary.